I only cramp at night, never when training. Does that narrow it down?

It takes the training-load explanation off the table, which leaves intake and fluid losses. Nocturnal cramps and disrupted sleep also get reported together generally, with nothing GLP-1-specific about the pairing, so the drug is not the automatic explanation for a night-time pattern. Electrolytes and kidney function can be measured, and that beats guessing which one it is.

Will they stop once I reach maintenance?

Every candidate cause here is downstream of active weight loss or of GI symptoms, and both ease at a stable dose and a stable weight. Cramps that persist once the deficit has gone are no longer explained by any of it, which makes them worth investigating rather than waiting out.

Should I train differently while this is happening?

The mechanism described here is neuromuscular fatigue arriving earlier, from less muscle working in an energy deficit. Session load and fuelling are what actually changed. Less volume in a session is a reasonable response to that, and there is more on holding onto lean tissue through the loss at working out on a GLP-1.

GLP-1 and Muscle Cramps

What this page establishes

Muscle cramps are not listed as a common labelled adverse reaction for semaglutide weight-management therapy.
Vomiting and diarrhoea, both common on this class, cause electrolyte as well as fluid loss, and FDA labelling links these GI reactions to dehydration-related harm.
Lean mass loss of roughly 25 to 40% of total weight lost occurs without structured training, which changes the loading a given workout represents.
Semaglutide injectable: 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg weekly, 4 weeks per step, 2.4 mg maintenance; 14.9% mean loss at 68 weeks (STEP 1).

Quick answers

I only cramp at night, never when training. Does that narrow it down?
It takes the training-load explanation off the table, which leaves intake and fluid losses.
Read the full answer
Nocturnal cramps and disrupted sleep also get reported together generally, with nothing GLP-1-specific about the pairing, so the drug is not the automatic explanation for a night-time pattern. Electrolytes and kidney function can be measured, and that beats guessing which one it is.
Will they stop once I reach maintenance?
Every candidate cause here is downstream of active weight loss or of GI symptoms, and both ease at a stable dose and a stable weight.
Read the full answer
Cramps that persist once the deficit has gone are no longer explained by any of it, which makes them worth investigating rather than waiting out.
Should I train differently while this is happening?
The mechanism described here is neuromuscular fatigue arriving earlier, from less muscle working in an energy deficit.
Read the full answer
Session load and fuelling are what actually changed. Less volume in a session is a reasonable response to that, and there is more on holding onto lean tissue through the loss at working out on a GLP-1.

Muscle cramps are not listed as a common labelled adverse reaction for semaglutide weight-management therapy, so the drug is not doing this to your muscles directly. That does not make new night cramps imaginary. The plausible causes are all downstream of what has changed around the drug: less food coming in, and with it less sodium, potassium and magnesium, fluid losses from GI symptoms, and a body that is training at a different mass than it was. Persistent or severe cramps deserve a blood test rather than a supplement guess.

Are cramps a recognised side effect?

No. They do not appear among the common labelled adverse reactions in semaglutide weight-management prescribing information, which is dominated by GI events. That absence is informative rather than dismissive: it means no drug-specific pharmacology has been identified, so the search for a cause looks elsewhere.

Exercise-associated and nocturnal cramps are incompletely understood in general. The two leading models are altered neuromuscular control arising from fatigue, and disturbance of fluid and electrolyte balance. Both of those shift on a GLP-1, which is why the complaint is plausible even without a labelled mechanism.

Fluid and electrolyte losses from GI symptoms

Vomiting and diarrhoea are common on this class, and both remove electrolytes along with water. FDA labelling links those GI reactions to dehydration and to serious kidney injury, in some cases requiring haemodialysis, which is the same pathway seen everywhere else in this cluster.

Cramps following a few days of GI illness are the easiest version of this to identify. Reduced circulating volume concentrates the problem, and it comes with other signals worth checking: urine output, urine colour, and dizziness on standing.

Worth separating two timescales. An acute episode of vomiting is an obvious event you can point at. A slow drift, where fluid intake has been quietly lower for two months because food volume fell, has no event attached to it and is the version people fail to notice.

Reduced dietary intake of sodium, potassium and magnesium

Halving portion size halves electrolyte intake, and nobody experiences that as a decision. Sodium in particular falls sharply when processed food and restaurant meals drop out of the diet, which for many people on this class happens quickly.

Claims that GLP-1s specifically deplete magnesium are not supported by trial data. There is no mechanism described in any label and no study measuring it. Reduced intake is a sufficient explanation without inventing a drug effect.

The magnesium claim No trial data support the idea that these drugs deplete magnesium. Lower intake from smaller portions explains the same observation without requiring a pharmacological effect.

Training load changes during weight loss

Lean mass loss of roughly 25 to 40% of total weight lost occurs in trials without structured training. STEP 1's DXA substudy put lean soft tissue at about 40% of weight lost and SURMOUNT-1 at about 26%, with a network meta-analysis near 25% for the class.

That changes what a given workout represents. The absolute load on the bar has not moved, but the muscle carrying it has less mass and is being fuelled from a deficit, so neuromuscular fatigue arrives earlier in the session. Earlier fatigue is one of the two main proposed cramp mechanisms, which makes training cramps a predictable consequence rather than a mystery.

Diabetes-specific considerations

Anyone also taking a diuretic has an additional route to electrolyte disturbance, and that is worth naming explicitly rather than leaving in a general list. Diuretics and GI losses stack.

Glucose fluctuations also produce symptoms that get described as cramping or as leg weakness. ADA Standards of Care 2026 instruct that sulfonylureas be discontinued or reduced and insulin adjusted when a GLP-1 receptor agonist is added, with bolus reduced 10 to 20% and basal about 10% if HbA1c is under 7.5%. If those adjustments have not been made, that is the more important conversation.

What actually needs investigating

Persistent or severe cramps warrant a check of electrolytes and kidney function rather than a trip to a supplement aisle. That is a clinician's call, and it is a cheap test that either finds something or rules it out.

The reason to test rather than supplement is that a normal electrolyte panel redirects the search toward training load, hydration and sleep, while an abnormal one changes management. Guessing gets you neither.

Sleep is worth mentioning too, because nocturnal cramps and disrupted sleep get reported together and each makes the other more noticeable. Nothing about that is GLP-1-specific. It is a reason not to assume the drug is the explanation when the pattern is a night-time one.

A first-person account, for context

Everything above is drawn from trial data and prescribing information. What that evidence cannot give you is what a GLP-1 block actually feels like week to week in someone training seriously.

Thomas Prommer, a competitive endurance athlete, has written up the side effects he did and did not get while training. Read it as one person's experience rather than as evidence. It is n=1, it is uncontrolled, and it describes an athlete population the trials on this page did not study. It is useful for exactly that reason and for no other.

When to contact a clinician

The first item is urgent. The rest warrant contact rather than an emergency department.

Cramps with dark urine after exercise, which can indicate rhabdomyolysis and needs urgent assessment.
Cramps alongside weakness, palpitations or confusion.
Cramps following days of vomiting or diarrhoea, which is the labelled dehydration pathway.
Persistent cramps with reduced urine output.
Cramps in anyone taking a diuretic, insulin or a sulfonylurea, where the medication review matters more than the cramp.

This is general information This page is educational and is not medical advice. Blood tests, supplement decisions and any adjustment to diabetes or diuretic medication belong to your clinician.

The evidence, one row per claim

Claim	Tier	Source
Muscle cramps are not listed as a common labelled adverse reaction for semaglutide weight-management therapy.	established	WEGOVY US Prescribing Information, FDA
Vomiting and diarrhoea, both common on this class, cause electrolyte as well as fluid loss, and FDA labelling links these GI reactions to dehydration-related harm.	established	OZEMPIC US Prescribing Information, FDA
Lean mass loss of roughly 25 to 40% of total weight lost occurs without structured training, which changes the loading a given workout represents.	established	Lean soft tissue during GLP-1 weight loss (PMC)
Claims that GLP-1s deplete magnesium specifically are not supported by trial data.	anecdotal	unsourced
Semaglutide injectable: 0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg weekly, 4 weeks per step, 2.4 mg maintenance; 14.9% mean loss at 68 weeks (STEP 1).	established	STEP 1
Tirzepatide: 2.5 mg initiation then 5 / 10 / 15 mg weekly maintenance; 16.0% / (10 mg intermediate) / 22.5% mean loss at 72 weeks (SURMOUNT-1).	established	Eli Lilly / NEJM

Sources

Where this comes from

Researched and edited by Thomas Prommer — biohacker, performance athlete, data enthusiast and health coach.

Every number on this page traces to a named source. There are 6 sourced claims below the fold, each with the document it came from.

Sources consulted: WEGOVY US Prescribing Information, OZEMPIC US Prescribing Information, Lean soft tissue during GLP-1 weight loss, unsourced, STEP 1 and 1 more.

Not clinically reviewed. This page was researched and written against primary regulatory and trial sources, and no clinician has checked it.

Sources last read 2026-08-23.

Keep reading

Educational content, reviewed 2026-08-23. Not medical advice, not a prescription, and not a substitute for a clinician who knows your history. Doses named here are label schedules or doses used in named trials, never a recommendation to you.